首页> 外文OA文献 >Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial

【2h】

Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial

机译：每周胰高血糖素样肽1受体激动剂，β1-蛋白质，血糖控制和减少2型糖尿病患者的糖尿病在多种胰岛素治疗中的糖尿病中的影响：随机试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Julio Rosenstock; Antonio Nino; Joseph Soffer; Lois Erskine; Andre Acusta; Jo Dole; Molly C. Carr; Jason Mallory; Philip Home;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: A comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro [J] . RosenstockJ., FonsecaV.A., GrossJ.L., Diabetes care . 2014,第8期

机译：在甘精胰岛素加口服剂控制不佳的情况下，改善在2型糖尿病中基础胰岛素的替代治疗：每周加用GLP-1受体激动剂阿比鲁肽与每日三次赖脯胰岛素治疗的比较
2. Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: Results over 52 weeks [J] . Leiter Lawrence A., Gross Jorge Luiz, Chow Francis, Journal of diabetes and its complications . 2017,第8期

机译：每周胰高血糖素肽-1受体激动剂Alphiglutide与糖尿病患者的基础胰岛素添加到基础胰岛素中，结果超过52周
3. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin [J] . Reusch J., Stewart M. W., Perkins C. M., Diabetes, obesity & metabolism . 2014,第12期

机译：每周一次的胰高血糖素样肽1受体激动剂阿比鲁肽的有效性和安全性（HARMONY 1试验）：52周主要终点来自一项随机，双盲，安慰剂对照试验，该试验针对不受吡格列酮控制的2型糖尿病患者，有或没有二甲双胍
4. Comparing artificial pancreas controlled by hybrid "closed-loop" machine learning (ML) trained algorithm to multi-daily injection (MDI), insulin pump without CGM and "sensor assisted" insulin pump therapies for Diabetes Type 1 (DT1) treatment [C] . Joan Carles Peiró International Conference on Data Analytics for Business and Industry: Way Towards a Sustainable Economy . 2020

机译：将通过混合“闭环”机器学习（ML）控制的人工胰腺培训算法对多日注于多日注射（MDI），胰岛素泵而没有CGM和“传感器辅助”胰岛素泵疗法1型（DT1）处理
5. A 4-month randomized controlled clinical trial of adjuvant Exenatide or Pramlintide versus insulin alone in pediatric type 1 diabetes mellitus: Effect on glycemic control. [D] . Withycombe, Sarah Elizabeth. 2010

机译：儿科1型糖尿病患者中艾塞那肽或普兰林肽与单独使用胰岛素的4个月随机对照临床试验：对血糖控制的影响。
6. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist Albiglutide on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial [O] . Julio Rosenstock, Antonio Nino, Joseph Soffer, 2020

机译：每周胰高血糖素样肽1受体激动剂β1-蛋白质血糖控制和减少2型糖尿病患者的糖尿病在多种胰岛素治疗中的糖尿病中的影响：随机试验
7. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial [O] . Julio Rosenstock, Antonio Nino, Joseph Soffer, 2020

机译：每周胰高血糖素样肽1受体激动剂，β1-蛋白质，血糖控制和减少2型糖尿病患者的糖尿病在多种胰岛素治疗中的糖尿病中的影响：随机试验

Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial

著录项

引文网络

相似文献

相关主题

期刊订阅